Baird analyst, Brian Skorney, is incrementally positive on Curis (NASDAQ: CRIS) after the announcement that the FDA has accepted the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE